Tandem Diabetes Care (Nasdaq:TNDM) announced today that it priced an offering of convertible senior notes worth $275 million. The San Diego-based automated insulin delivery technology developer plans to sell the notes, due 2029, to qualified institutional buyers. It upsized the offering from the previously announced $250 million aggregate principal amount. The company also offered initial […]
Funding Roundup
Know Labs to raise up to $12M for non-invasive CGM tech
Know Labs (NYSE:KNW) announced that it entered into a funding agreement for an investment worth up to $12 million. The Seattle-based company executed a $4 million close as part of this investment with Lind Global Fund II. The Lind Partners, a New York-based institutional fund manager, manages Lind Global Fund II. Funding helps Know Labs […]
Vivani prices $15M offering to support long-term drug delivery implant
Vivani Medical (Nasdaq:VANI) announced today that it entered into a securities purchase agreement worth $15 million in proceeds. The company entered the agreement with an institutional investor. It covers the purchase of just shy of 4 million shares of common stock and warrants to purchase common stock. Alameda, California-based Vivani priced the shares at $3.80 […]
Irish startup Gasgon Medical looks to raise €4M for IV delivery tech
Gasgon Medical reportedly hopes to raise more than $4.3 million (€4 million) to support its technology for fast, accurate IV delivery. The Cork, Ireland-based medtech startup already has commitments from returning lead investors, according to The Business Post. Founded in 2018, Gasgon develops a medical device that assists healthcare providers in IV (intravenous) administration delivery. The […]
Modular Medical closes $10M public offering
Modular Medical (Nasdaq:MODD) announced that it closed an underwritten public offering worth proceeds of $10 million. The San Diego-based insulin pump maker offered just over 9 million shares of its common stock. It sold each share of common stock to the public at a price of $1.10 per share. Manchester Explorer — managed by Modular […]
Clearside Biomedical prices $15M offering
Clearside Biomedical (Nasdaq:CLSD) announced that it entered into a securities purchase agreement worth proceeds of approximately $15 million. The company agreed with institutional investors and an existing stockholder on the purchase and sale of 11.1 million shares of common stock and warrants. It set the offer price for one share of common stock and warrant […]
RenovoRx closes $6.1M private placement
RenovoRx announced today that it closed a private placement bringing in gross proceeds of approximately $6.1 million. Los Altos, California-based RenovoRx develops precision oncology therapies based on a local drug delivery platform. Closing this funding round extends the company’s cash runway as it conducts its pivotal TIGer-PaC Phase III clinical trial. It expects the funds […]
Insulet enters into new credit agreement worth $487.5M in term loans
Insulet (Nasdaq:PODD) announced that it entered into an amended credit agreement to replace existing term loans. The automated insulin delivery technology developer entered into the agreement with Morgan Stanley Senior Funding. This agreement amended a credit agreement dated May 4, 2021. Pursuant to the agreement, the $487.5 million in term loans outstanding under the existing […]
Aptar wins FDA contract to study low global warning potential metered dose inhalers
Aptar Pharma announced today that it entered into a contract with the FDA to work on low global warming potential (low-GWP) inhalers. The FDA enlisted Aptar to study the challenges of developing low-GWP propellant metered dose inhalers (MDIs). The Crystal Lake, Illinois-based company expects its study to help define the potential target product profile of […]
1nhaler raises $2.5M for sustainable single-use inhaler
1nhaler announced today that it raised $2.5 million (£2 million) to develop a sustainable single-use dry powder inhaler. The Scotland-based drug delivery device developer cited limited inhalable medicine development due to a number of reasons. Those include accessibility, cost, performance and environmental impact. Its own development could enable the delivery of several dry powder drugs […]